BCG Vaccine and Its Potential Protection Against COVID-19

Introduction to SARS-CoV-2

Over the past year, the SARS-CoV-2 virus has spread globally, prompting scientists and health experts to gather extensive information to support efforts in combating COVID-19. One positive aspect of this rapid spread is the opportunity for researchers to analyze large sample sizes in observational studies.

Observations on BCG Vaccine Efficacy

In the initial months of the pandemic, a correlation was noted between countries that utilize the BCG vaccine and improved patient outcomes. The BCG vaccine, traditionally used against tuberculosis, has previously shown non-specific protective effects against various diseases. This has led to the hypothesis that it may reduce susceptibility to SARS-CoV-2 or enhance outcomes for those who contract the virus. A recent study published in The Journal of Clinical Investigation aimed to test this hypothesis.

Study Methodology

Researchers focused on a high-exposure group: healthcare workers. Early in the pandemic, the CORALE group, consisting of frontline clinicians and scientists, formed to conduct observational studies. They established two cohorts, one of which included 6,201 frontline healthcare workers recruited from various locations in Los Angeles. Participants completed an electronic survey collecting data on demographics, vaccination history, COVID-19 diagnosis, and symptoms. Blood samples were also taken to test for SARS-CoV-2 antibodies, with collection occurring between May 11 and June 18, 2020.

Statistical Analysis and Findings

A statistical analysis investigated the relationship between BCG vaccination and SARS-CoV-2 infection. The demographic data allowed for control over variables like age and sex. Out of the original cohort, 1,836 had received the BCG vaccine, while 4,275 had not. Overall, 3.5% of the cohort tested positive for SARS-CoV-2 antibodies. Vaccinated individuals were slightly less likely to report COVID-19 symptoms in the previous six months and significantly less likely to have a medical diagnosis or a positive RT-PCR test for COVID-19.

The antibody seroprevalence results reflected this trend, with only 2.7% of those vaccinated testing positive for antibodies, compared to 3.8% in the unvaccinated group. Notably, the vaccinated cohort was older and had higher rates of comorbidities, such as hypertension and cardiovascular disease, yet still showed better outcomes regarding SARS-CoV-2 infection.

Comparison with Other Vaccines

The authors also analyzed whether similar protective effects were observable with other vaccines, including meningococcal, pneumococcal, and influenza vaccines. Their analysis indicated that these vaccines did not demonstrate the same protective effect as the BCG vaccine.

Study Limitations and Conclusions

One limitation of the study is that the vaccinated cohort exhibited higher levels of comorbidities. Although this finding could support the argument for a protective effect of the BCG vaccine, it is possible that individuals with more comorbidities practiced more cautious behavior, leading to lower infection rates. Thus, the reduced infection levels in the vaccinated group may be attributed to behavior modifications rather than a direct protective effect of the BCG vaccine.

Despite these considerations, the results strongly suggest that the BCG vaccine offers some level of protection. While the precise mechanism behind this effect remains unclear, similar observations have been noted in other respiratory conditions. The compelling observational evidence supports broader use of the BCG vaccine, particularly for those at higher risk of severe COVID-19 complications.

References

Written by Michael McCarthy
1. Noval Rivas M, Ebinger JE, Wu M, Sun N, Braun J, Sobhani K, et al. BCG vaccination history associates with decreased SARS-CoV-2 seroprevalence across a diverse cohort of healthcare workers. The Journal of Clinical Investigation. 2020.
Image by Arek Socha from Pixabay.